PGEN heads into its June 18 earnings call with short sellers in an extended retreat — but still holding a position large enough to keep the stock structurally contested.
Short interest has fallen from a peak above 21.8% of the free float in mid-April to just under 19.8% now. That decline spans roughly six weeks and represents a meaningful unwind. Yet 19.8% remains high in absolute terms. Roughly one in five shares in the free float is still borrowed short, and the short score — ORTEX's composite measure of bearish pressure — has actually crept back up to 74.4 this week after dipping to 71.8 in mid-May. The short score ranks PGEN in the 7th percentile of its universe, meaning 93% of stocks face less bearish positioning. That is a notable figure even accounting for the headline SI decline.
The borrow market itself tells a calmer story. Cost to borrow is just 0.58% — effectively zero friction for a short seller. Availability, at roughly 185% of estimated short interest, is loose: there are nearly two shares available to borrow for every one currently shorted. That is well within normal range and has actually widened sharply since early May, when availability was nearer 108–116%. What that shift tells you is that a batch of shorts covered over the past three weeks, releasing inventory back into the lending pool. The covering was orderly — not a panic. Options positioning corroborates the calmer tone: the put/call ratio has fallen to 0.62, well below its 20-day average of 0.83 and about 1.2 standard deviations below the mean. A month ago it was running above 1.10. Options traders have rotated from defensive to more neutral, perhaps even gently constructive.
Analysts are aligned on the bull side. Both Citizens and HC Wainwright raised targets to $11.00 in mid-May — right after the May 13 earnings print — while maintaining positive ratings. That puts the consensus target against a $4.24 stock, implying roughly 160% upside on the Street's math. The bull case centres on Papzimeos, Precigen's first commercial product, which has reportedly exceeded early sales expectations. Bulls argue a strong balance sheet, a diverse clinical pipeline across PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007, and active label-expansion work give the company multiple shots on goal. Bears counter that commercialisation is fragile, clinical and regulatory risk remains substantial, and Papzimeos alone may not move the needle on a loss-making P&L. The PE multiple is deeply negative, and EPS surprise ranks in the 71st percentile — meaning beat history is genuinely above average, but the company is still burning cash.
The May 13 print matters as context for June 18. The stock jumped 12.7% on earnings day and held most of the gain, adding another 4.7% over the following five days. The March 25 print was more dramatic: a 24.3% single-day move followed by a 25.6% five-day run. The pattern is clear — PGEN has been rewarding positive earnings reactions sharply when they come. Shorts who covered in the weeks after May 13 presumably took that lesson to heart. What remains to be seen heading into June 18 is whether the commercial Papzimeos ramp and any pipeline updates are enough to sustain that pattern, or whether the still-elevated 19.8% short base reasserts itself if expectations disappoint.
The institutional picture adds one footnote worth noting. Third Security, LLC holds a dominant 29% of shares and has not moved its position. Executive Chairman Randal Kirk sold roughly $13.8 million in stock in late March at $3.30 — a price the stock has since traded well above at $4.24. That sale was flagged here; no subsequent insider activity appears in the data. Point72 added 18.3 million shares in the most recent quarter, a significant accumulation for a stock of this size.
The June 18 earnings call is the next hard catalyst. The question is less about whether the Papzimeos launch is progressing and more about the quantitative ramp metrics and any update on the clinical pipeline that could justify — or challenge — the Street's $11 consensus target.
See the live data behind this article on ORTEX.
Open PGEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
